Antonio Giordano, Breast Medical Oncologist at Dana-Farber Cancer Institute, shared a post on X:
“Potential practice change EVeRa trial presented by Erica Mayer, Dana-Farber’s Breast Oncology Center, Giradestrant + Everolimus.
Awaiting regulatory approval, the winner is increased use of Everolimus + Fulvestrant from Monday!”
More posts featuring Erica Mayer on OncoDaily.
